Blog: BIONIK LABORATORIES CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

On September 8, 2022, Bionik Laboratories Corp. (the “Company”) issued a press
release to announce the acquisition of a rehabilitation center in Clermont, FL,
the first in the Company’s planned strategic national rollout.

The center is revenue-producing, profitable and has an existing roster of
patients and referral sources. The Company intends for it to be rebranded to a
specialized neuro-recovery center that will showcase the Company’s technology
and solutions, providing treatment to patients with stroke, brain and spinal
cord injuries, in addition to its historic treatment offerings. This first
center will be named Tower Aquatic and be rebranded as a BIONIK Company.

The Company financed the acquisition of the rehabilitation center with a secured
convertible loan from an existing investor of the Company who is also one of its
directors, as previously announced, indicating continuing support and belief in
this new strategy.

The press release, which is furnished as Exhibit 99.1 to this Current Report on
Form 8-K, is incorporated herein by reference. The information in this report
(including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not
be deemed to be “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section. This report will not be deemed an admission as to the materiality
of any information herein (including Exhibit 99.1).

Forward-Looking Statements

Any statements contained in this Current Report on Form 8-K that do not describe
historical facts may constitute forward-looking statements. Forward-looking
statements, which involve assumptions and describe our future plans, strategies,
and expectations, are generally identifiable by use of the words “may,”
“should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,”
“estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations, including
plans or objectives relating to the design, development and commercialization of
robotic rehabilitation products and the roll-out of its recently-announced
Neuro-Recovery Centers of Excellence strategy, (ii) a projection of income
(including income/loss), earnings (including earnings/loss) per share, capital
expenditures, dividends, pipeline of potential sales, capital structure or other
financial items, (iii) the Company’s future financial performance, including as
a result of the acquisition and rebranding of the Company’s Neuro-Recovery
Centers of Excellence, and the future financial performance of any such Centers
of Excellence the Company may acquire or launch (iv) the market and projected
market for our existing and planned products and services and (v) the
assumptions underlying or relating to any statement described in points (i),
(ii), (iii) or (iv) above. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or circumstances, and
may not be realized because they are based upon the Company’s current
projections, plans, objectives, beliefs, expectations, estimates and
assumptions, and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control. Actual results and the
timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ materially from
expected or desired results may include, without limitation, the Company’s
inability to obtain additional financing or increase revenue, the inability to
meet listing standards to uplist to a national stock exchange, the significant
length of time and resources associated with the development and sale of our
products and related insufficient cash flows and resulting illiquidity, the
continued impact on the Company’s business as a result of the Covid-19 pandemic,
the Company’s inability to expand the Company’s business, including its
recently-launched Neuro-Recovery Centers of Excellence strategy, significant
government regulation of medical devices and the healthcare industry, lack of
product diversification, volatility in the price of the Company’s raw materials,
and the Company’s failure to implement the Company’s business plans or
strategies. These and other factors are identified and described in more detail
in the Company’s filings with the SEC. The Company does not undertake to update
these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

Exhibit  Description
  99.1     Press release
104      Cover Page Interactive Data File (embedded within the Inline XBRL

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s